フィブロネクチンの抑制は,心不全のモデルにおいて,線維症を緩和し,心臓の機能を改善する
Iñigo Valiente-Alandi1,2, Sarah J Potter3, Ane M Salvador4
1Department of Pediatrics (I.V.-A., A.E.S., T.S., A.M.G., C.P., M.A.S., J.H., J.D.M., B.C.B.), University of Cincinnati College of Medicine, OH.
Circulation
|April 15, 2018
まとめ
心臓の線維芽細胞におけるフィブロネクチン (FN) ポリメリゼーションを阻害すると,線維症が減り,損傷後の心臓の機能が改善されます. FNポリメリゼーションをターゲットにすることで 心不全の新たな治療法が生まれます
科学分野:
- 心血管生物学
- 繊維症の研究
- 再生医療
背景:
- フィブロネクチン (FN) ポリメリゼーションは,損傷後のコラーゲン収納と心筋線維細胞 (MF) の膨張に不可欠です.
- FNポリメリゼーションまたは線維細胞特異的なFN発現の変化は,心臓の再構成と機能に影響を与える可能性があります.
研究 の 目的:
- 心臓の線維芽細胞におけるFNポリメリゼーションを阻害する治療の可能性を調査する.
- 筋膜芽細胞の活動,線維症,心機能に対するFN阻害の影響を評価する.
主な方法:
- マウスとヒトのMFに対するFNポリメリゼーション阻害剤pUR4のインパクトを in vitroで評価した.
- I/ R後の野生型のマウスにpUR4を投与し,心臓機能,線維症,MFマーカーを分析した.
- 細胞特異的なFNの役割を評価するために,誘導可能な,線維細胞に制限されたFN遺伝子除去されたマウスを使用した.
主要な成果:
- pUR4はFNとコラーゲンの堆積を減らし,MFの増殖と移動を in vitroで弱めた.
- In vivo pUR4治療は,I/ R後4週間まで,MFマーカー,中性粒子の浸透,および心筋機能障害を減少させた.
- 繊維細胞特異的なFN切除により,心臓の重要な保護作用が認められ,増幅と線維症が減少した.
結論:
- FNポリメリゼーションや線維細胞のFN発現を阻害すると,不良な心臓再構成や線維症が軽減されます.
- 心筋線維症と心不全の治療には,FNポリメリゼーションをターゲットにすることが有望な治療戦略です.
さらに関連する動画
関連する概念動画
01:30Heart Failure V: Medical Management
184
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
184
01:29Heart Failure II: Pathophysiology
633
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
633
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
857
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
857
01:22Heart Failure Drugs: β-Blockers
710
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
710
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K